feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouIndiaIndia
You
bookmarksYour BookmarkshashtagYour Topics
Trending
Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2026 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

Home / Health / Beyond Needles: The Future of Insulin for Diabetes Patients

Beyond Needles: The Future of Insulin for Diabetes Patients

4 Dec, 2025

•

Summary

  • Insulin delivery, a cornerstone of diabetes care, remains largely unchanged for a century.
  • Inhaled insulin offers rapid absorption, mimicking physiological responses.
  • Delivery method innovation is crucial for patient adherence and better diabetes outcomes.
Beyond Needles: The Future of Insulin for Diabetes Patients

While diabetes care has seen vast advancements over the last century, insulin delivery methods have remained static, primarily relying on subcutaneous injections. This traditional approach, though effective, presents significant challenges for patients, particularly those requiring multiple daily injections.

The frequent need for injections, the social stigma, and the general burden of self-management can lead to decreased adherence, missed doses, and ultimately, poorer health outcomes. Recognizing this, research has explored alternative delivery systems, with inhaled insulin emerging as a significant innovation.

Clinically tested in trials involving over 200 patients in India, inhaled insulin offers a needle-free option. Administered via a dry powder inhaler, it enters the bloodstream rapidly, effectively managing post-meal glucose spikes and reducing the risk of hypoglycemia. This method represents a critical step towards improving patient experience and long-term diabetes management.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
Current insulin injections can be burdensome due to frequency, discomfort, and social stigma, impacting patient adherence and outcomes.
Inhaled insulin is administered via a dry powder inhaler, rapidly entering the bloodstream to manage blood sugar after meals.
Innovation in insulin delivery is crucial to overcome patient barriers, improve adherence, and achieve better long-term glycaemic control.

Read more news on

Indiaside-arrowHealthside-arrow
trending

Chelsea beats West Ham 3-2

trending

Liverpool, Newcastle face injury woes

trending

WWE Royal Rumble in Riyadh

trending

Barcelona faces Elche in LaLiga

trending

Goretzka staying at Bayern Munich

trending

ICC T20 World Cup squads

trending

Gold, silver ETFs crashed

trending

Curran, Pandya T20Is stats compared

trending

Suryakumar Yadav T20I record

You may also like

Beyond BMI: Unlocking Your True Diabetes Risk

29 Jan • 12 reads

article image

Toxic 'Forever Chemicals' Raise Gestational Diabetes Risk

16 Jan • 109 reads

article image

India's Youth Face Early Heart Risks

23 Dec, 2025 • 207 reads

article image

Early GDM: A Higher Risk for Future Diabetes

14 Dec, 2025 • 242 reads

article image

Insulin Not a Failure: Expert on Type 2 Shift

10 Dec, 2025 • 206 reads

article image